Starting from the observation that in some AML patients from early Phase I studies, the long-term WT1 peptide vaccination resulted in prolonged MRD negativity, a new generation of studies addressed the capacity of WT1-based vaccines to prevent relapse in patients who had achieved CR after chemotherapy (161–164). Here, WT1 is linked to acute myeloid leukemia.